Actively Recruiting
Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis
Led by British Columbia Cancer Agency · Updated on 2025-09-22
190
Participants Needed
4
Research Sites
581 weeks
Total Duration
On this page
Sponsors
B
British Columbia Cancer Agency
Lead Sponsor
T
Terry Fox Research Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are looking for better ways of understanding and treating pancreatic cancer. The purpose of this study is to see how useful it is to look for changes and characteristics in your genes (molecules that contain instructions for the development and functioning of the cells) and the genes within the tumour. These characteristics may be useful in choosing treatments for patients in the future. Changes (mutations) in genes have been shown to be an important characteristic in cancers. Looking at differences in genes in patients with advanced pancreatic ductal adenocarcinomas and comparing this information with response to their initial chemotherapy treatment may help to learn which treatments may be better for certain patients after initial treatment.
CONDITIONS
Official Title
Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histological and/or radiological diagnosis of metastatic PDAC. Patients without a histological diagnosis must have confirmatory tumour biopsy before treatment.
- Planned first-line systemic therapy with FOLFIRINOX or gemcitabine plus nab-paclitaxel (GP), alone or with investigational agents.
- Age 18 years or older.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Adequate organ function.
- Life expectancy greater than 90 days as judged by the investigator.
- Ability to provide informed consent.
- Measurable disease by RECIST 1.1 criteria.
- Presence of a tumour lesion suitable for core needle biopsy with at least 3 cores safely obtainable under CT or ultrasound guidance.
- Fit enough to safely undergo tumour biopsy as judged by the investigator.
- Ability to lie on back (supine) for more than 60 minutes.
- For archival cohort: availability of archival tumour sample (previous biopsy or surgical specimen).
You will not qualify if you...
- No distant or lymph node metastases; borderline resectable or locally advanced PDAC patients are excluded.
- Prior systemic therapy for advanced disease; adjuvant chemotherapy after surgery is allowed.
- Currently receiving any anti-cancer therapy.
- Not fit for combination chemotherapy as judged by the investigator.
- Presence of brain metastases.
- Female patients with a positive pregnancy test.
- Considered unsafe for study participation by the investigator for any medical or non-medical reason.
- Unable to comply with study assessments and follow-up.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Tom Baker Cancer Centre
Calgary, Alberta, Canada, T2N 4N2
Actively Recruiting
2
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Withdrawn
3
BC Cancer - Vancouver
Vancouver, British Columbia, Canada, V5Z 4E6
Actively Recruiting
4
The Ottawa Hospital
Ottawa, Ontario, Canada, K1H 8L6
Active, Not Recruiting
Research Team
D
Daniel J Renouf, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here